Update shared on 27 Nov 2025
Fair value Decreased 8.42%Analysts have revised their price target for Archean Chemical Industries downward from ₹714.57 to ₹654.43, citing slightly lower forecasts for revenue growth and profit margins based on the latest review of fundamentals.
What's in the News
- An upcoming board meeting is scheduled for November 14, 2025, at 16:30 IST to review and approve the un-audited financial results for the quarter and half year ended September 30, 2025 (Key Developments).
- The board will consider the Limited Review Report from the Statutory Auditors regarding the standalone and consolidated un-audited financial results for the same period (Key Developments).
- Financial results will be published in newspapers in accordance with Regulation 47 of the SEBI LODR (Key Developments).
Valuation Changes
- Consensus Analyst Price Target has fallen from ₹714.57 to ₹654.43.
- Discount Rate has decreased slightly, moving from 13.52% to 13.47%.
- Revenue Growth estimates have been reduced from 30.86% to 30.31%.
- Net Profit Margin projections are now lower, shifting from 27.64% to 26.75%.
- Future P/E ratio forecast has declined from 18.67x to 17.84x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.